within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02C_OtherGynecologicals.G02CB02_Lisuride;

model Lisuride
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 0.00022472222222222224,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.195,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.009116666666666667,
    Tlag = 900,
    Vdp = 2.38,
    k12 = 0.00015416666666666668,
    k21 = 0.00015416666666666668);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lisuride</td></tr><tr><td>ATC code:</td><td>G02CB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>195</td><td>L</td></tr>
    <tr><td>clearance:</td><td>809</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lisuride is an ergot-derived dopamine agonist formerly used in the management of Parkinson's disease, hyperprolactinemia, and migraine prophylaxis. It acts mainly on dopamine D2 receptors and to a lesser degree on serotonin receptors. Its clinical use has largely been superseded by newer medications, and lisuride is not widely approved or in use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02CB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lisuride;
